Skip navigation

Ironwood Pharmaceuticals takes bigger 1Q loss

Ironwood Pharmaceuticals Inc. reported a larger first-quarter loss Thursday as it prepared to file for approval of its constipation drug candidate linaclotide. Full story

Infinity Pharma gains ground on analyst upgrade

Shares of Infinity Pharmaceuticals Inc. traded higher Monday after a Piper Jaffray analyst upgraded the stock, saying he expects the stock to rise as investors wait for clinical data on a cancer drug candidate. Full story

Vertex Pharmaceuticals takes bigger 1Q loss

Vertex Pharmaceuticals Inc. reported a larger first-quarter loss Tuesday as it awaits regulators' decision on its experimental hepatitis C drug candidate. Full story

Pain Therapeutics reports Remoxy abuse study data

Pain Therapeutics Inc. on Monday reported clinical study results that may indicate its pain drug candidate Remoxy is more difficult to abuse than OxyContin. Full story

XenoPort plans study on potential MS drug

XenoPort Inc. said Monday that it reached an agreement with the Food and Drug Administration to start a late-stage study on the drug candidate arbaclofen placarbil as a potential treatment for multiple sclerosis patients with spasticity. Full story

Medivation CEO on Failed Drug

   Dr. David Hung, CEO of Medivation, discusses the failure of Dimebon, an Alzheimer's drug candidate.

Sponsored Links


Experimental 0besity drug showing promise

All octopuses are venomous

advertisement | ad info